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Abstract
Background: In Italy, the prevalence of non-tuberculous mycobacteria (NTM) in human infections is largely
unknown. Herein, we report the epidemiology of NTM infections in a region of central Italy, Tuscany, over the last
11 years, and provide a review of the recent literature on NTM isolation rates in different geographic regions.
Methods: The complete collection of NTM strains isolated from a total of 42,055 clinical specimens at the
Laboratory of Clinical Mycobacteriology of Pisa University Hospital, Italy, from 1 January 2004 to 31 December 2014
was included.
Results: In our setting, in the period 2004–2014 a total of 147 patients had cultures positive for NTM. The number
of NTM isolates increased considerably from five isolates in 2004 to 29 in 2014; a sharp increase occurred in the last
3 years. Overall, 16 NTM species were isolated; the most common were M. avium, M. intracellulare and M. gordonae
detected in respectively in 41.5, 14.3 and 11.6 % of NTM patients. In general, NTM isolates were largely prevalent in
people older than 60 (57.8 %); patients aged 1–10 year-old almost exclusively yielded M. avium and M. intracellulare.
Of the 147 NTM clinical isolates, 76.2 % were from respiratory specimens, 10.9 % from lymph nodes, 2.7 % from
blood (yielding exclusively M. avium), and the remaining 10.2 % from other clinical specimens.
Conclusions: The observed increase in NTM isolation rate in our setting is in keeping with the general increase in
NTM infections reported worldwide in the past two decades, although the distribution of the NTM prevalent
species differs by geographic region.
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Background
Non-tuberculous mycobacteria (NTM) include all Myco-
bacterium species other than Mycobacterium tubercu-
losis complex and Mycobacterium leprae. NTM are a
group of over 150 enviromental species, but, due to re-
cent advancement of molecular techniques, novel spe-
cies are being identified [1]. NTM are generally
endowed with low pathogenicity to humans [2], however
some species are associated with a variety of human dis-
eases, especially concomitantly to particular risk factors
[3]; respiratory tract infections are the most frequent,
followed by lymphadenitis in children, disseminated in-
fections in severely immunocompromised patients and
skin infections [4]. Although significant differences in
geographic distribution of NTM have been observed [5],
species belonging to Mycobacterium avium complex
(MAC), particularly M. avium and M. intracellulare, are
the most frequently reported; other important human
NTM pathogens include slowly growing mycobacteria,
usually community-acquired from environmental or ani-
mal sources, such as Mycobacterium kansasii, Mycobac-
terium xenopi, Mycobacterium malmoense, and rapidly
growing mycobacteria typically hospital-acquired, such
as Mycobacterium abscessus, Mycobacterium chelonae
and Mycobacterium fortuitum. A considerable increase
in both incidence and prevalence of NTM infections has
been observed worldwide in the past two decades, not
only for the development of new and more sensitive mo-
lecular methods for NTM identification, but also for a
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Table 1 Species, patients’ age and site of infection of NTM isolated at the Clinical Mycobacteriology Laboratory of Pisa University Hospital during years 2004–2014
NTM species No. of
isolates (%
of total
isolates)
No. of isolates (% of species isolates)
Patient age range Site of isolation
1–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 >80 Respiratory tract Blood Lymph node Othera
M. avium 61 (41.5) 8 (13.1) 2 (3.3) 1 (1.6) – 8 (13.1) 7 (11.5) 9 (14.8) 20 (32.8) 6 (9.8) 40 (65.6) 4 (6.6) 11 (18.0) 6 (9.8)
M. intracellulare 21 (14.3) 3 (14.3) – – 2 (9.5) – 2 (9.5) 5 (23.8) 6 (28.6) 3 (14.3) 17 (81.0) – 4 (19.0) –
M. gordonae 17 (11.6) – – – 3 (17.6) 4 (23.5) 2 (11.8) 3 (17.6) 4 (23.5) 1 (5.9) 14 (82.4) – – 3 (17.6)
M. xenopi 14 (9.5) – – – 5 (35.7) 2 (14.3) 2 (14.3) 4 (28.6) – 1 (7.1) 14 (100.0) – – –
M. fortuitum 10 (6.8) – – – – 1 (10.0) 2 (20.0) 3 (30.0) 4 (40.0) – 7 (70.0) – – 3 (30.0)
M. kansasii 7 (4.8) – – 1 (14.3) – – 1 (14.3) 4 (57.1) 1 (14.3) – 7 (100.0) – – –
M. celatum 3 (2.0) 1 (33.3) – – – – – 1 (33.3) 1 (33.3) – 2 (66.6) – 1 (33.3) –
M. abscessus 2 (1.4) – – – – – – – 1 (50.0) 1 (50.0) 1 (50.0) – – 1 (50.0)
M. chelonae 2 (1.4) – – – 1 (50.0) 1 (50.0) – – – – 2 (100.0) – – –
M. marinum 2 (1.4) – – – – 2 (100.0) – – – – – – – 2 (100.0)
M. lentiflavum 2 (1.4) – – – – – – 2 (100.0) – – 2 (100.0) – – –
M. simiae 2 (1.4) – – – – – 1 (50.0) – 1 (50.0) – 2 (100.0) – – –
M. scrofulaceum 1 (0.7) – – – – – –– – 1 (100.0) – 1 (100.0) – – –
M. triplex 1 (0.7) – – – – – – – – 1 (100.0) 1 (100.0) – – –
M. phocaicum 1 (0.7) – – – – – – – – 1 (100.0) 1 (100.0) – – –
M. bolletii 1 (0.7) – – – – – – – 1 (100.0) – 1 (100.0) – – –
Total 147 (100.0) 12 (8.2) 2 (1.4) 2 (1.4) 11 (7.5) 18 (12.2) 17 (11.6) 31 (21.1) 40 (27.2) 14 (9.5) 112 (76.2) 4 (2.7) 16 (10.9) 15 (10.2)
ainclude isolates from urine, stool, skin, gastric lavage and other body fluids
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real increase in NTM disease cases [6]. Several European
countries have published studies about NTM epidemi-
ology showing an increase in NTM isolated from human
clinical samples [7–9], however NTM epidemiology in
Italy is largely unknown. The aim of the present survey
is to provide an overview of the epidemiology and recent
trend of NTM infections in a region of central Italy,
Tuscany, over the last 11 years.
Methods
Clinical isolates
The survey include the complete collection of 147 NTM
strains, isolated from the same number of patients, from
a total of 42,055 clinical specimens at the Laboratory of
Clinical Mycobacteriology of Pisa University Hospital,
Italy, during an 11-year study period from 1 January
2004 to 31 December 2014. In the case of multiple con-
secutive positive cultures from the same patient, only
the first isolate was included in the present study. All
strains were isolated by using the BACTEC MGIT960
liquid culture system (Becton Dickinson, USA) and were
identified by molecular probes (InnoLipa [Innogenetics,
Belgium] and/or Genotype CM/AS [Hain Lifescience,
Germany]) and by a multiplex PCR designed to discrim-
inate MAC organisms [10]. Patients’ clinical information,
including gender, age and site of infection, was obtained
from clinical records; distinction between community-
versus hospital-acquired infections was not possible.
Research ethics approval was not necessary for
retrospective studies in our Institution; informed con-
sent was not required as the data were analyzed
anonymously.
Results and discussion
Between January 2004 and December 2014, a total of
42,055 clinical specimens collected from approximately
15,000 patients with suspected mycobacterial infection
were tested; a total of 595 patients had cultures positive
for mycobacteria; M. tuberculosis complex and NTM
species were isolated from 448 (75.3 %) and 147 (24.7 %)
patients, respectively. A total of 16 NTM species were
isolated (Table 1), the most common belonging to the
MAC (n = 82, 55.8 %); in particular, M. avium subsp.
hominissuis was detected in 61 (41.5 %) and M. intracel-
lulare in 21 (14.3 %) patients. M. gordonae was the third
prevalent species (n = 17, 11.6 %), followed by M. xenopi
(n = 14, 9.5 %), M. fortuitum (n = 10, 6.8 %), and M. kan-
sasii (n = 7, 4.8 %). In general, the species distribution of
NTM isolated in our setting was close to that reported
earlier in an inventory study of NTM in the European
Union, which included Italy [7]. Similarly to other stud-
ies [9, 11], the NTM infections were not associated with
gender, although M. intracellulare and M. kansasii ap-
peared to be more common in men (16 males vs 5 fe-
males, P = 0.002 for M. intracellulare; 6 males vs 1
females, P = 0.003 for M. kansasii, by χ2 analysis). In
general, NTM isolates were largely prevalent in people
older than 60 (n = 85, 57.8 %)¸ patients aged 1–10 year-
old almost exclusively yielded M. avium and M. intracel-
lulare (11 out of 12, 91.7 % in total), the most commonly
encountered species in mycobacterial lymphadenitis in
children [12]. Of the 147 NTM clinical strains, 112
(76.2 %) were isolated from respiratory tract specimens
(sputum and bronchoalveolar lavage), 4 (2.7 %) from
blood, 16 (10.9 %) from lymph nodes, and the remaining
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Fig. 1 NTM isolated at the Clinical Mycobacteriology Laboratory of Pisa University Hospital during years 2004–2014. Only the six prevalent
species, out of the 16 isolated during the survey period, are individually reported with different column fillings; the other NTM species (M.
celatum, M. abscessus, M. chelonae, M. marinum, M. lentiflavum, M. simiae, M. scrofulaceum, M. triplex, M. phocaicum and M. bolletii) are grouped
together (see figure legend at the right side)
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15 isolates (10.2 %) from other specimens, including
urine, stool, skin, gastric lavage and other body fluid. In
particular, all the blood specimens yielded M. avium,
which was also the prevalent species isolated from ade-
nitis episodes; M. xenopi and M. kansasii were isolated
only from pulmonary specimens; M. marinum was iso-
lated exclusively from skin samples. These results reflect
the ability of the mycobacterial species to infect and
localize in different body sites [3].
The distribution over time of the NTM isolates is re-
ported in Fig. 1. As shown, the number of NTM isolates
increased considerably from five isolates in 2004 to 29 in
2014; a sharp increase occurred in the last 3 years. In
2014, in particular, M. avium and M. intracellulare were
the prevalent isolates representing 58.6 % of total NTM
isolates; the increase in MAC isolates occurred mostly in
people aged over 60 with pulmonary infections, as also
reported by others [9, 13, 14]. Notably, M. kansasii, a
pulmonary pathogen not reported before 2012 in our
setting, was repeatedly isolated in the last 3 years, repre-
senting 9.6 % of total NTM isolates; M. gordonae, which
is considered a non-pathogenic enviromental contamin-
ant, was the third most frequently isolated species.
On the whole, the increase in isolation rate of NTM in
our setting in recent years is in keeping with several re-
ports all over the world [7–9, 11, 15–19]. However, it is
Table 2 Recent studies on isolation rates of NTM from human clinical specimens in different settings
Setting Years Prevalent NTM species % of total isolates Trend Reference
Tuscany (Italy) 2004–2014 M. avium 41.5 Increase This study
M. intracellulare 14.3
M. gordonae 11.6
England, Wales and Northern Ireland 1995–2006 M. avium-intracellulare 42.9 Increase 9
M. malmoense 13.7
M. kansasii 12.5
Scotland 2000–2010 M. avium complex 48.1 No clear trend 13
M. malmoense 17.7
M. abscessus 9.8
The Netherlands 2000–2006 M. avium complex 39.0 Increase 14
M. gordonae 14.1
M. kansasii 7.4
Croatia 2006–2010 M. gordonae 42.9 Increase 11
M. xenopi 15.5
M. fortuitum 11.5
Athens (Greece) 2007–2013 M. gordonae 13.9 No trend 20
M. avium 13.1
M. fortuitum 12.2
Virginia (USA) 2001–2009 M. avium complex 40.9 Increase 22
M. gordonae 28.7
M. abscessus 4.5
Oregon (USA) 2007–2012 M. avium-intracellulare 86 Increase 21
M. chelonae/abscessus 6
Shangai (China) 2008–2012 M. kansasii 45.0 Increase 23
M. intracellulare 20.8
M. chelonae/abscessus 14.9
Cheonan (Korea) 2005–2011 M. intracellulare 51.3 Increase 24
M. avium 14.7
M. kansasii 7.8
South Korea 2001–2011 M. avium complex 53 Increase 25
M. abscessus-massiliense 25
M. fortuitum 6
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worthy to note that the distribution of the species of
NTM isolated from clinical specimens differs markedly
by geographic region. Table 2 summarizes a selection of
the recent literature reporting NTM isolation rates in
different settings and geographic regions. In Europe, M.
avium and M. intracellulare were the most common
species, reaching prevalence rates approximately as high
as 40–60 % in Italy, United Kingdom and the
Netherlands. Interestingly, in the United Kingdom, al-
though M. avium-intracellulare, M. malmoense and M.
kansasii were the prevalent species, the rise in NTM iso-
lates was mostly due to M. gordonae generally isolated
from pulmonary specimens in patients over 60 year-old
[9, 13]; similarly, in a study from Croatia, the highest in-
crease in NTM isolation frequency was attributed to M.
gordonae and M. fortuitum [11]; also studies from the
Netherlands and Athens (Greece) showed high rates of
M. gordonae isolates [14, 20]. In the United States the
prevalent NTM species were M. avium complex, M. gor-
donae and M. abscessus [21, 22], while in Eastern Asia
the most frequent were M. avium complex, M. kansasii
and M. abscessus and M. fortuitum [23–25].
Conclusions
In conclusion, the present study, although not represent-
ing a population-based investigation, shows an increase
in NTM isolation rate in our setting, which is consistent
with the increasing rates seen elsewhere, and provides a
snapshot of the prevalent NTM species in our setting.
The clinical significance of the increased isolation rate of
NTM from human specimens observed in the present
study remains largely unknown for the difficulties to in-
terpret whether the NTM isolations are related to colon-
isation or disease. Further studies involving detailed
clinical data are needed to better understand the
changes in NTM epidemiology.
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